Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00344682 · ClinicalTrials.gov registry record · Phase 4

Memantine Augmentation of Antidepressants

A Phase 4 study of Depressive Disorder, sponsored by University of Massachusetts, Worcester.

Completed
Registry status
Phase 4
Development phase
31
Enrollment target
1
Study location

NCT00344682 is a Phase 4 study of Depressive Disorder that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 31 participants, below the 331-participant average among 47 other Depressive Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00344682, a Phase 4 study of Depressive Disorder, has completed, sponsored by University of Massachusetts, Worcester.

COMPLETED
Registry status
Phase 4
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG memantine

Study Locations (1)

Massachusetts

  • Center for Psychopharmacologic Research and Treatment (University of Massachusetts Medical School) - Worcester

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2006-06
Est. Completion 2011-12
Phase Phase 4

What the Registry Record Tells You About NCT00344682

The ClinicalTrials.gov registry entry for NCT00344682 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 331-participant average among 47 other Depressive Disorder trials with a reported enrollment target (91% lower). The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00344682 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00344682 about?

NCT00344682 is a clinical study titled "Memantine Augmentation of Antidepressants". This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.

What is the current status of trial NCT00344682?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2006-06. Estimated completion is 2011-12.

What conditions does trial NCT00344682 study?

This clinical trial studies the following conditions: Depressive Disorder.

What interventions are being tested in trial NCT00344682?

The interventions under investigation include: Placebo (DRUG), memantine (DRUG).

Who is sponsoring clinical trial NCT00344682?

This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00344682 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.